Cargando…
Postoperative C-reactive protein kinetics predict postoperative complications in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis
BACKGROUND: Relatively high morbidity rates are reported after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). However, early predictors of complications after CRS plus HIPEC have not been identified. The aim of this study was to evaluate the predictive role of ea...
Autores principales: | Asmar, Antoine El, Bendavides, Melissa, Moreau, Michel, Hendlisz, Alain, Deleporte, Amélie, Khalife, Maher, Donckier, Vincent, Liberale, Gabriel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694318/ https://www.ncbi.nlm.nih.gov/pubmed/33243287 http://dx.doi.org/10.1186/s12957-020-02081-6 |
Ejemplares similares
-
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer
por: Piso, Pompiliu, et al.
Publicado: (2004) -
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of gastric cancer with peritoneal carcinomatosis
por: Ellison, Lynne M., et al.
Publicado: (2017) -
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy With Mitomycin C Used for Colorectal Peritoneal Carcinomatosis
por: Roh, Seung Jae, et al.
Publicado: (2020) -
The Impact of Multidisciplinary Team Approach on Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis
por: Hung, Hao-Chien, et al.
Publicado: (2021) -
Clinical course for patients with peritoneal carcinomatosis excluded from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
por: Rodt, Anne Peen, et al.
Publicado: (2013)